SCHEMBL3059321

SCHEMBL3059321

Fc1ccc(-c2nc(-c3ccccc3)no2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.78
NPC1 O15118 7/20 0.69
RAB9A P51151 7/20 0.69
NFKB1 P19838 3/20 0.69
NFKB2 Q00653 3/20 0.69
RELA Q04206 3/20 0.69
SMN1; SMN2 Q16637 8/20 0.67
HSD17B10 Q99714 4/20 0.67
TP53 P04637 4/20 0.67
MAPT P10636 3/20 0.67
S1PR1 P21453 1/20 0.63
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
KDM4E B2RXH2 2/20 0.62
PKM P14618 1/20 0.62
MAPK1 P28482 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
CYP1A2 P05177 1/20 0.62
CA2 P00918 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28593073 1.00 NR1H4 (0.78) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL17640602 0.88 NR1H4 (0.91) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL321073 0.88 NR1H4 (0.91) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL1473020 0.88 NR1H4 (1.00) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL3064778 0.87 NR1H4 (0.61) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL16592595 0.84 ACHE (0.57) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL2810636 0.83 NR1H4 (1.00) NR1H4NPC1RAB9ANFKB1NFKB2
SCHEMBL1505380 0.83 TPH1 (0.61) NR1H4NPC1RAB9ASMN1; SMN2TP53
SCHEMBL8163626 0.83 TPH1 (0.61) NR1H4NPC1RAB9ASMN1; SMN2TP53
SCHEMBL28788077 0.82 NPC1 (0.55) NR1H4NPC1RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113502491-A Electrochemical preparation method of Tioxazafen and atrareum intermediate 湖南大学 2021-10-15 CN disclosed
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2017-07-20 US disclosed
US-9045442-B2 Antibacterial compounds and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-06-02 US disclosed
US-9045442-B2 Antibacterial compounds and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-06-02 US disclosed
US-9045442-B2 Antibacterial compounds and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-06-02 US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-20100261673-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2010-10-14 US disclosed
US-20100261673-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2010-10-14 US disclosed
US-20100261673-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2010-10-14 US disclosed
WO-2009082398-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2009-07-02 WO disclosed
WO-2009082398-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2009-07-02 WO disclosed
WO-2009041972-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2009-04-02 WO disclosed
WO-2009041972-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2009-04-02 WO disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207704-A1 Novel Oxadiazole Compounds S1PR3, S1PR1, S1PR2 NR1H4 390/4885NPC1 1268/4885RAB9A 2582/4885
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 NR1H4 3038/4885NPC1 732/4885RAB9A 2618/4885
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 NR1H4 390/4885NPC1 1268/4885RAB9A 2582/4885
US-20100261673-A1 ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME SPOUT1, MRPL21, NPEPPS NR1H4 2734/4885NPC1 4451/4885RAB9A 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.